Table 3.

ILD subjects—clinical features and treatment

	Isolated ILD (N = 18)	PM/DM-ILD (N = 13)	p
FVC % predicted—mean (± SD)	71.5 (± 21.1)	72.3 (± 22.5)	0.93
DLCO % predicted—mean (± SD)	49.7 (± 16.6)	64.4 (± 29.3)	0.15
CT features—mean (± SD)
Ground glass	1.44 (± 0.86)	1.15 (± 0.80)	0.35
Consolidation	0.17 (± 0.51)	0.38 (± 0.77)	0.35
Reticulation	2.17 (± 0.79)	1.31 (± 0.63)	0.0029
Traction	1.89 (± 0.90)	0.92 (± 0.86)	0.0055
Fulminant ILD—no. (%)	6 (33)	2 (15)	0.41
Serum CK, IU/L—median (range)	75 (24–240)	265 (82–8015)	0.0001
Antisynthetase antibodies—no. (%)	3 (17)	12 (92)	< 0.0001
Treatment—no (%)	11 (65)	13 (100)	0.024
Prednisone	11 (65)	11 (85)	0.41
Immunomodulators	5 (29)	12 (92)	0.0008